Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keefer

Showing results (1101-1110 of 1,129) with videos related to

Pageof 113
Sort By:
The Journal of Experimental Medicine|May 5, 2022
Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancerRenuka Raman, Jacques A Villefranc, Timothy M Ullmann, et al.
JCI Insight|May 22, 2020
Robust antibody and cellular responses induced by DNA-only vaccination for HIVStephen C De Rosa, Srilatha Edupuganti, Yunda Huang, et al.
Human Vaccines & Immunotherapeutics|May 29, 2012
Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse eventsClaudia Schmidt, Carol Smith, Burc Barin, et al.
The Lancet. HIV|May 1, 2024
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trialIan Frank, Shuying S Li, Nicole Grunenberg, et al.
Nature Communications|May 20, 2022
Automated next-generation profiling of genomic alterations in human cancersLaurel A Keefer, James R White, Derrick E Wood, et al.
The Journal of Infectious Diseases|October 18, 2015
Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083Stephen R Walsh, Zoe Moodie, Andrew J Fiore-Gartland, et al.
Vaccines|December 10, 2020
Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP<sup>®</sup> DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy AdultsSrilatha Edupuganti, Stephen C De Rosa, Marnie Elizaga, et al.
Science (New York, N.Y.)|May 17, 2003
The 2002 Denali fault earthquake, Alaska: a large magnitude, slip-partitioned eventDonna Eberhart-Phillips, Peter J Haeussler, Jeffrey T Freymueller, et al.
The Journal of Infectious Diseases|October 5, 2023
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120Zvavahera Mike Chirenje, Fatima Laher, One Dintwe, et al.
The New England Journal of Medicine|October 9, 2013
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccineScott M Hammer, Magdalena E Sobieszczyk, Holly Janes, et al.
Pageof 113

Showing results (1101-1110 of 1,129) with videos related to

Sort By:
Pageof 113
The Journal of Experimental Medicine|May 5, 2022
Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancerRenuka Raman, Jacques A Villefranc, Timothy M Ullmann, et al.
JCI Insight|May 22, 2020
Robust antibody and cellular responses induced by DNA-only vaccination for HIVStephen C De Rosa, Srilatha Edupuganti, Yunda Huang, et al.
Human Vaccines & Immunotherapeutics|May 29, 2012
Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse eventsClaudia Schmidt, Carol Smith, Burc Barin, et al.
The Lancet. HIV|May 1, 2024
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trialIan Frank, Shuying S Li, Nicole Grunenberg, et al.
Nature Communications|May 20, 2022
Automated next-generation profiling of genomic alterations in human cancersLaurel A Keefer, James R White, Derrick E Wood, et al.
The Journal of Infectious Diseases|October 18, 2015
Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083Stephen R Walsh, Zoe Moodie, Andrew J Fiore-Gartland, et al.
Vaccines|December 10, 2020
Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP<sup>®</sup> DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy AdultsSrilatha Edupuganti, Stephen C De Rosa, Marnie Elizaga, et al.
Science (New York, N.Y.)|May 17, 2003
The 2002 Denali fault earthquake, Alaska: a large magnitude, slip-partitioned eventDonna Eberhart-Phillips, Peter J Haeussler, Jeffrey T Freymueller, et al.
The Journal of Infectious Diseases|October 5, 2023
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120Zvavahera Mike Chirenje, Fatima Laher, One Dintwe, et al.
The New England Journal of Medicine|October 9, 2013
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccineScott M Hammer, Magdalena E Sobieszczyk, Holly Janes, et al.
Pageof 113